Kate Rochlin - Apr 27, 2025 Form 4 Insider Report for IN8BIO, INC. (INAB)

Role: Chief Operating Officer
Signature: /s/ Jason Minio, Attorney-in-Fact
Stock symbol: INAB
Transactions as of: Apr 27, 2025
Transactions value $: $2,267
Form type: 4
Date filed: 5/7/2025, 08:45 PM
Previous filing: Feb 7, 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Rochlin Kate	Chief Operating Officer	C/O IN8BIO, INC., 350 5TH AVE. SUITE 5330, NEW YORK	/s/ Jason Minio, Attorney-in-Fact	2025-05-07	0001898521

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	INAB	Common Stock	Options Exercise	$2.27K	+12.3K	+28.68%	$0.18	55.2K	Apr 30, 2025	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	INAB	Series A Warrants (right to buy)	Disposed to Issuer		-12.3K	-100%		0	Apr 27, 2025	Common Stock	12.3K	$0.45	Direct	F1, F2, F3
transaction	INAB	Series A Warrants (right to buy)	Award		+12.3K			12.3K	Apr 27, 2025	Common Stock	12.3K	$0.18	Direct	F1, F2
transaction	INAB	Series A Warrants (right to buy)	Options Exercise	$0	-12.3K	-100%	$0.00	0	Apr 30, 2025	Common Stock	12.3K	$0.18	Direct	F2
transaction	INAB	Series B Warrants (right to buy)	Disposed to Issuer		-12.3K	-100%		0	Apr 27, 2025	Common Stock	12.3K	$1.50	Direct	F2, F3, F4
transaction	INAB	Series B Warrants (right to buy)	Award		+12.3K			12.3K	Apr 27, 2025	Common Stock	12.3K	$0.45	Direct	F2, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 and later amended on October 4, 2024 with an exercise price of $0.45 per share and expiration date of October 4, 2025. On April 27, 2025, the warrant's exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025.
F2	Fully vested and exercisable.
F3	The reported securities are included within 12,295 units purchased by the Reporting Person on December 13, 2023 for $1.22 per unit. Each unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 12,295 shares of common stock.
F4	The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share. The exercise price was reduced to $0.45 per share.